Eugenol

Phase 2Small molecule

HHITEC-Institute of Medical Sciences

Eugenol is one of 3 small molecule programs targeting Alveolar Osteitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alveolar OsteitisNot yet recruiting

Alveolar OsteitisPhase 2

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Alveolar Osteitis

#DrugCompanyPhaseTrials

Eugenol

HHITEC-Institute of Medical Sciences

Phase 2

1 2

Alvogyl

WWatim Medical & Dental College

Phase 2

1 3

Platelet-Rich Fibrin (PRF)

FFederal University of São Paulo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alveolar Osteitis1 trial

A Comparative Single Blind Clinical Study on the Effect of Alvogyl, Eugenol, and Nigella Sativa (Black Seed Oil) for Alveolar Osteitis.

Not yet recruiting·HHITEC-Institute of Medical Sciences·Phase 2·NCT06823544·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Eugenol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Eugenol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Eugenol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — HITEC-Institute of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHITEC-Institute of Medical Sciences

Eugenol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Alveolar Osteitis1 trial

References

Drug Info

Quick Facts

Related News